NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

GeoVax Labs, Inc. (GOVX) Stock Analysis

GeoVax Labs, Inc. (GOVX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GOVX

$0.23

+$0.01 (+2.25%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GOVX with… →

GOVX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.23
Previous Close
$0.23
Day's Range
0.22–0.23
52-Week Range
0.22–15.18
Volume
146.18K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.69
Valuation
Market Cap
$2.35M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−8.84
Financials (FY)
Revenue (FY)
$2.49M−37.06%
Net Income (FY)
−$21.46M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.10M
1-Year Return
−98.40%
Dividend and dates
Avg Volume
771.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GOVX closed at $0.23, −98.40% over 1 year.

GeoVax Labs, Inc. (GOVX) has a market capitalization of $2.35M.

In fiscal 2025, GOVX reported revenue of $2.49M.

GOVX Stock Return by Calendar Year

GeoVax Labs, Inc. (GOVX) return since Sep 2020: what $10,000 became

1 year
$10,000 $160
−98.40%
5 years
$10,000 $2
−99.98%
Since Sep 2020
$10,000 $2
−99.98%

If you had invested $10,000 in GeoVax Labs, Inc. (GOVX) at the close on September 25, 2020, the earliest close on record here, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −75.21% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−94.57%
2025−93.08%
2024−54.39%
2023−42.70%
2022−82.60%
2021+7.10%
2020 (partial year)+14.97%

As of October 21, 2026.

GOVX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.49M−$21.46M−862.3%
2024$3.95M−$24.99M−632.0%
2023$0.00−$25.97M—
2022$81.53K−$14.02M−17,198.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.49M—−$21.64M−$21.46M−862.3%
2024$3.95M—−$25.14M−$24.99M−632.0%
2023$0.00—−$26.74M−$25.97M—
2022$81.53K—−$14.03M−$14.02M−17,198.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

GeoVax Labs, Inc. (GOVX) is capitalised at $2.35M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 19 employees.

GOVX last closed at $0.23 on October 21, 2026. That is +$0.01 (+2.25%) against the previous close. Over the past 52 weeks the price has ranged from $0.22 to $15.18. The latest close sits 5.55% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.49M. Against the prior fiscal year total of $3.95M, that is a change of −37.06%. The same year closed with a net loss of $21.46M. Trailing earnings per share are −8.84.

Across the 4 fiscal years on file, revenue moves from $81.53K in 2022 to $2.49M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 3.69. Annualized volatility over the trailing 6 years is 163.52%. The trailing one-year total return is −98.40%. Across 5 years the annualized return works out at −82.63%.

Growth & Income

No dividend is on file for GOVX.

The strongest complete calendar year on file is 2021 at +7.10%; the weakest is 2025 at −93.08%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −94.57% year to date.

Peer Comparison

GeoVax Labs, Inc. (GOVX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GeoVax Labs, Inc. GOVX $2.35M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. GeoVax Labs, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Visit website →